Abstract:Here, we present combined experimental and theoretical studies on the spectroelectrochemical properties of 8-aminoquinoline (8AQ). 8AQ is a model molecule for drugs that can chelate copper(II) ions, and thus it may find applications in halting the development of Alzheimer’s disease. Although over a hundred years have passed since Alzheimer’s disease (AD) was first described, it remains incurable to this day. According to one of the leading hypotheses, peptides from the β-amyloid (Aβ) group are responsible for the development of AD. By binding copper(II) ions, Aβs form complexes whose presence promotes the formation of harmful, highly active compounds called reactive oxygen species (ROS) and reactive nitrogen species (RNS). In a series of recent studies, we investigated the differences in electrochemical properties of Cu(II)-complexes with the amyloids Aβ(11-16) and Aβ(3-16) with their pyroglutamated versions, pAβ(11-16) and pAβ(3-16). [1,2] These results showed that the pyroglutamate amyloids are conducive to Cu(II)-reduction at a potential associated with ROS production. Given the abundance of pyroglutamated amyloids in senile plaques, this could have important consequences for AD pathophysiology. Overproduction of ROS and RNS can cause neuron death. Therefore, substances that can aid in removing copper(II) ions from β-amyloids could block the formation of ROS and RNS. Recently, a new quinoline derivative with unique properties has undergone preclinical studies. However, little is known about the redox properties of such molecules, which may be crucial in the early stages of testing potential therapeutic substances. Therefore, we aimed to perform electrochemical and spectroelectrochemical studies of a model molecule, 8-aminoquinoline, whose redox properties were not yet well characterized To fully characterize both anodic and cathodic processes, we used cyclic and pulse voltammetry over a wide range of pH values, including physiological (pH=7.4). In addition, the experimental results were supported by DFT-based computational studies exploring the energy landscapes of the possible reactions and advancing understanding of the electrochemical phenomena. The kind of electrochemical tests presented here may prove of crucial importance for the development of more effective drugs against AD. The high failure rate and relatively poor performance of the recently approved treatment indicates the need to extend preclinical studies with new, so far unused techniques, allowing a more complete picture to be obtained of the effectiveness and toxicity of the potential drug candidates. [1] M.Z. Wiloch, N. Baran, M. Jönsson‐Niedziółka, The Influence of Coordination Mode on the Redox Properties of Copper Complexes with Aβ(3‐16) and Its Pyroglutamate Counterpart pAβ(3‐16), ChemElectroChem. 9 (2022). https://doi.org/10.1002/celc.202200623. [2] M.Z. Wiloch, M. Jönsson-Niedziółka, Very small changes in the peptide sequence alter the redox properties of Aβ(11–16)-Cu(II) and pAβ(11–16)-Cu(II) β-amyloid complexes, Journal of Electroanalytical Chemistry. 922 (2022) 116746. https://doi.org/10.1016/j.jelechem.2022.116746.

Investigation on Small Molecules Targeting Cu(I) Preventing Copper-Mediated Neurotoxicity

Rationally Designed Cu(I) Ligand to Prevent CuAβ-Generated ROS Production in the Alzheimer's Disease Context

Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of Α-Synuclein.

Identification of 2-subsituted benzothiazole derivatives as triple-functional agents with potential for AD therapy

Tripeptide GGH as the Inhibitor of Copper-Amyloid-β-Mediated Redox Reaction and Toxicity

A multifunctional anti-AD approach: Design, synthesis, X-ray crystal structure, biological evaluation and molecular docking of chrysin derivatives

Sulfur-bridging the gap: investigating the electrochemistry of novel copper chelating agents for Alzheimer's disease applications

Next-generation Cu(II) selective peptide shuttles prevent Cu(Aβ)-induced toxicity and microglial activation in organotypic hippocampal slices

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Ionophoric polyphenols selectively bind Cu(2+), display potent antioxidant and anti-amyloidogenic properties, and are non-toxic toward Tetrahymena thermophila

Mechanistic approaches for chemically modifying the coordination sphere of copper–amyloid-β complexes

Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β-Amyloid Cellular Pathologies through a Metal-Dependent Mechanism

Preliminary Studies of a Novel Bifunctional Metal Chelator Targeting Alzheimer's Amyloidogenesis

A Copper-Selective Sensor and Its Inhibition of Copper-Amyloid Beta Aggregation

A cocktail of Cu 2+ - and Zn 2+ -peptoid-based chelators can stop ROS formation for Alzheimer's disease therapy

A coumarin-based multifunctional chemosensor for Cu 2+ /Al 3+ as an AD theranostic agent: Synthesis, X-ray single crystal analysis and activity study

Synthesis of three new copper(II) compounds for chemodynamic therapy against cancer cells

Effects of Cyclen and Cyclam on Zinc(ii)- and Copper(ii)-Induced Amyloid Beta-Peptide Aggregation and Neurotoxicity.

Quercetin Attenuates Copper-Induced Apoptotic Cell Death and Endoplasmic Reticulum Stress in SH-SY5Y Cells by Autophagic Modulation

The Molecular Mechanism for Human Metallothionein-3 to Protect Against the Neuronal Cytotoxicity of Aβ1–42 with Cu Ions

Spectroelectrochemical and Computational Study of Quinoline Based Molecules - Potential Anti-Alzheimer’s Drugs